父源免疫抑制剂暴露对性功能、生殖激素、生育力、妊娠及子代结局影响的系统综述
该系统综述检索Embase、MEDLINE等数据库至2019年8月31日,纳入161篇原始研究,其中50篇涉及妊娠与子代结局、130篇涉及性健康结局。柳氮磺吡啶和环磷酰胺对精子质量有明显负面影响,秋水仙碱、甲氨蝶呤和西罗莫司的影响不明确;妊娠与子代结局资料稀少但未报告重大不良效应。证据总体尚不充分。
要点
- 柳氮磺吡啶和环磷酰胺对精子质量有明显负面影响。
- 秋水仙碱、甲氨蝶呤和西罗莫司对精子质量的影响不明确。
- 妊娠与子代结局资料稀少,但未报告与父源免疫抑制剂暴露相关的重大不良效应。
核心结论
- 关于有生育意愿男性使用免疫抑制剂安全性的证据尚不充分。
- 缺乏评估和报告男性性功能、生育力及生殖结局的统一标准是导致该结果的重要原因。
- 未来需要开展该领域研究,最好采用标准化方法。
研究设计与样本
- 系统综述,检索Embase、MEDLINE ALL、Cochrane Central Register of Trials、Web of Science Core Collection、Google Scholar及欧洲和美国临床试验注册库,检索时间从建库至2019年8月31日。
- 共识别5867篇参考文献,最终纳入161篇符合标准的文章,其中50篇涉及妊娠与子代结局,130篇涉及性健康结局。
- 因数据异质性未能进行Meta分析。
主要发现
- 除大型斯堪的纳维亚队列外,大多数纳入文章参与者数量较少。
- 柳氮磺吡啶和环磷酰胺对精子质量有明显负面影响。
- 秋水仙碱、甲氨蝶呤和西罗莫司对精子质量的影响不明确。
- 在3篇文章中,强直性脊柱炎患者暴露于肿瘤坏死因子-α抑制剂后精子质量改善。
- 妊娠与子代结局信息稀少,但未报告与父源免疫抑制剂暴露相关的重大不良效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 因数据异质性未能进行Meta分析。
- 除大型斯堪的纳维亚队列外,大多数纳入文章参与者数量较少。
- 关于有生育意愿男性使用免疫抑制剂安全性的证据尚不充分。
- 缺乏评估和报告男性性功能、生育力及生殖结局的统一标准。
- 妊娠与子代结局信息稀少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Information regarding the possible influence of immunosuppressive drugs on male sexual function and reproductive outcomes is scarce. Men diagnosed with immune-mediated diseases and a wish to become a father represent an important neglected population since they lack vital information to make balanced decisions about their treatment. OBJECTIVE AND RATIONALE: The aim of this research was to systematically review the literature for the influence of paternal immunosuppressive drug use on many aspects of male sexual health, such as sexual function, fertility, pregnancy outcomes and offspring health outcomes. SEARCH METHODS: A systematic literature search was performed in the bibliographic databases: Embase (via Elsevier embase.com), MEDLINE ALL via Ovid, Cochrane Central Register of Trials (via Wiley) and Web of Science Core Collection. Additionally, Google Scholar and the Clinical trial registries of Europe and the USA were searched. The databases were searched from inception until 31 August 2019. The searches combined keywords regarding male sexual function and fertility, pregnancy outcomes and offspring health with a list of immunosuppressive drugs. Studies were included if they were published in English and if they included original data on male human exposure to immunosuppressive drugs. A meta-analysis was not possible to perform due to the heterogeneity of the data. OUTCOMES: A total of 5867 references were identified, amongst which we identified 161 articles fulfilling the eligibility criteria. Amongst these articles, 50 included pregnancy and offspring outcomes and 130 included sexual health outcomes. Except for large Scandinavian cohorts, most of the identified articles included a small number of participants. While a clear negative effect on sperm quality was evident for sulfasalazine and cyclophosphamide, a dubious effect was identified for colchicine, methotrexate and sirolimus. In three articles, exposure to tumour necrosis factor-α inhibitors in patients diagnosed with ankylosing spondylitis resulted in improved sperm quality. The information regarding pregnancy and offspring outcomes was scant but no large negative effect associated with paternal immunosuppressive drug exposure was reported. WIDER IMPLICATIONS: Evidence regarding the safety of immunosuppressive drugs in men with a wish to become a father is inconclusive. The lack of standardisation on how to evaluate and report male sexual function, fertility and reproduction as study outcomes in men exposed to immunosuppressive drugs is an important contributor to this result. Future research on this topic is needed and should be preferably done using standardised methods.
引用
- Perez-Garcia LF, Dolhain RJEM, Vorstenbosch S, et al. The effect of paternal exposure to immunosuppressive drugs on sexual function, reproductive hormones, fertility, pregnancy and offspring outcomes: a systematic review. Hum Reprod Update. 2020. PMID: 32743663. doi:10.1093/humupd/dmaa022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。